These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35702632)

  • 1. Firm Exit during the COVID-19 Pandemic: Evidence from Japan.
    Miyakawa D; Oikawa K; Ueda K
    J Jpn Int Econ; 2021 Mar; 59():101118. PubMed ID: 35702632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring business-level expectations and uncertainty: survey evidence and the COVID-19 pandemic.
    Chen C; Senga T; Zhang H
    Jpn Econ Rev (Oxf); 2021; 72(3):509-532. PubMed ID: 34248384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of COVID-19 on Japanese firms: mobility and resilience via remote work.
    Kawaguchi D; Kitao S; Nose M
    Int Tax Public Financ; 2022; 29(6):1419-1449. PubMed ID: 36092538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fiscal Stimulus and Firms' Sales and Capital Expenditure During the Global Financial Crisis.
    Correa-Caro C; Medina L; Poplawski-Ribeiro M; Sutton B
    Comp Econ Stud; 2021; 63(3):489-535. PubMed ID: 34366561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Family Exit and Firms' Investment Efficiency Based on Dynamic Changes: Evidence from Chinese Family Firms.
    Wang T; Peng Q; Song H
    Comput Intell Neurosci; 2022; 2022():7572891. PubMed ID: 35958788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of COVID-19 related government response stringency and support policies: Evidence from European firms.
    Janzen B; Radulescu D
    Econ Anal Policy; 2022 Dec; 76():129-145. PubMed ID: 35959486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of COVID-19 on the valuations of non-financial European firms.
    Abbas Rizvi SK; Yarovaya L; Mirza N; Naqvi B
    Heliyon; 2022 Jun; 8(6):e09486. PubMed ID: 35634174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Firms' participation in the Swiss COVID-19 loan programme.
    Fuhrer LM; Ramelet MA; Tenhofen J
    Swiss J Econ Stat; 2021; 157(1):2. PubMed ID: 33968811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zombies, again? The COVID-19 business support programs in Japan.
    Hoshi T; Kawaguchi D; Ueda K
    J Bank Financ; 2023 Feb; 147():106421. PubMed ID: 36568842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of COVID-19 government support and its consequences for firm liquidity and solvency.
    Lalinsky T; Pál R
    Struct Chang Econ Dyn; 2022 Jun; 61():305-335. PubMed ID: 35317527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does patenting always help new firm survival? Understanding heterogeneity among exit routes.
    Kato M; Onishi K; Honjo Y
    Small Bus Econ (Dordr); 2022; 59(2):449-475. PubMed ID: 38624688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Product line transformation, foreign sales, and firm value: Evidence from COVID-19 pandemic governance in urban China.
    Wang L; Yu J; Chan KC
    Res Int Bus Finance; 2021 Dec; 58():101487. PubMed ID: 36540340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Government policies and firm performance in the COVID-19 pandemic era: a sectoral analysis.
    Turkson D; Addai NB; Chowdhury F; Mohammed F
    SN Bus Econ; 2021; 1(12):168. PubMed ID: 34841266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the COVID-19 pandemic on business expectations.
    Meyer BH; Prescott B; Sheng XS
    Int J Forecast; 2022; 38(2):529-544. PubMed ID: 35185229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Productivity and firm exit during the COVID-19 crisis: cross-country evidence.
    Muzi S; Jolevski F; Ueda K; Viganola D
    Small Bus Econ (Dordr); 2023; 60(4):1719-1760. PubMed ID: 38625239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small business under the COVID-19 crisis: Expected short- and medium-run effects of anti-contagion and economic policies.
    Kawaguchi K; Kodama N; Tanaka M
    J Jpn Int Econ; 2021 Sep; 61():101138. PubMed ID: 36569643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can R&D investment reduce the impact of COVID-19 on firm performance?-Evidence from India.
    Biswas S
    J Public Aff; 2021 Oct; ():e2773. PubMed ID: 34899063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sadder but Wiser: The Role of SARS Imprinting and Firms' Recovery During the COVID-19 Pandemic.
    Yao H; Wang J; Bo Q; Li M
    Front Psychol; 2022; 13():917337. PubMed ID: 35756304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Market risk, financial distress and firm performance in Vietnam.
    Vo DH
    PLoS One; 2023; 18(7):e0288621. PubMed ID: 37467279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of corporate insolvency during COVID-19 pandemic. Evidence from France.
    Stef N; Bissieux JJ
    Int Rev Law Econ; 2022 Jun; 70():106063. PubMed ID: 35261416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.